The first artificial intelligence (AI) diagnostic system to gain clearance from the U.S. Food and Drug Administration beat out all predetermined benchmarks, achieving "high diagnostic accuracy" for patients with certain forms of diabetic retinopathy, according to clinical trial findings. IDx, the developer of the system, IDx-DR, published its results this week in the peer-reviewed journal Nature Digital Medicine. The paper provides an inside look into a technology that could transform how the industry diagnoses diabetic retinopathy, a condition that can cause blindness, bringing the process from the specialist's office to primary care -- without the need for a clinician to interpret the results. READ: First-of-Its-Kind AI Tool for Diabetic Retinopathy Detection Approved by FDA "This is formerly uncharted territory in healthcare, making it especially critical that we ensure the highest level of safety before introducing autonomous AI into patient care," Michael D. Abràmoff, M.D., Ph.D., IDx's founder and president and the study's principal investigator, said in a statement. In April, the FDA cleared IDx-DR, which analyzes images of the eye, for detection of "more than mild" diabetic retinopathy in adults with diabetes.

Nasa is working to contain a small leak onboard the International Space Station. The issue appears to be contained and the people on board the station do not appear to be under any immediate threat. But it did trigger a real alarm through the floating lab, which sent astronauts scrambling to find the cause of the problem. The crew was forced to check for the source of the leak by closing separate modules on the space station and finding which of them may be damaged. It was eventually tracked down in part of the Soyuz MS-09 spacecraft, which arrived at the station in early June carrying a crew of astronauts.

The first FDA-approved AI system for diagnosing eye diseases caused by diabetes is completely autonomous, and doesn't require a doctor to interpret the results. Several corporations including Google and DeepMind have been working on building algorithms for diabetic retinography, a leading cause of blindness amongst adults. The first biz to release a device approved by the US Food and Drug Administration (FDA) earlier this year in April, however, is less well-known. IDx LLC, an AI diagnostics company based in Iowa, developed the tool known as IDx-DR. The details about the system were published in a paper in Nature Digital Medicine on Tuesday.

A team of researchers at the Medical University of Vienna has recently evaluated the effectiveness of machine learning strategies to identify bacteraemia in patients affected by systemic inflammatory response syndrome (SIRS). Their study, published in Scientific Reports, gathered discouraging results, as machine learning methods could not achieve better accuracy than current diagnostic techniques. Bacteraemia is a frequent medical condition characterized by the presence of bacteria in the blood, with a mortality rate ranging between 13 percent and 21 percent. Past research suggests that a number of factors are associated with the risk of developing this condition, including advanced age, urinary or indwelling vascular catheter, chemotherapy, and immunosuppressive therapies. Diagnosing bacteraemia early is of crucial importance for the survival of affected patients, as they require prompt treatment with appropriate antibiotics.

Engineers at the center have taught a computer how to detect tiny specks of lung cancer in CT scans, which radiologists often have a difficult time identifying. The artificial intelligence system is about 95 percent accurate, compared to 65 percent when done by human eyes, the team said. "We used the brain as a model to create our system," said Rodney LaLonde, a doctoral candidate and captain of UCF's hockey team. "You know how connections between neurons in the brain strengthen during development and learn? We used that blueprint, if you will, to help our system understand how to look for patterns in the CT scans and teach itself how to find these tiny tumors."

Doctors may soon have help in the fight against cancer thanks to the University of Central Florida's Computer Vision Research Center. Engineers at the center have taught a computer how to detect tiny specks of lung cancer in CT scans, which radiologists often have a difficult time identifying. The artificial intelligence system is about 95 percent accurate, compared to 65 percent when done by human eyes, the team said. "We used the brain as a model to create our system," said Rodney LaLonde, a doctoral candidate and captain of UCF's hockey team. "You know how connections between neurons in the brain strengthen during development and learn? We used that blueprint, if you will, to help our system understand how to look for patterns in the CT scans and teach itself how to find these tiny tumors."

Decision trees are one of my favorite models. They are simple, and they are powerful. In fact most high performing Kaggle entries are a combination of XGBoost, which is variant of decision tree, and some very clever feature engineering. The concept behind decision trees is refreshingly straightforward. Imagine creating a data set by recording the time you left your house, and noting whether you arrived at work on time.

Let us build a crude decision tree which predicts the outcome in probabilities (In Scikit learn, predict method returns the predicted classes while the predict_proba method returns the predicted probabilities. What do you think would be most simple and easy way to predict the probabilities? I have touched it up a little bit. The fit method accepts a dataframe(data) and a string for the target attribute(target). Both of the them are then assigned to the object.

When it comes to artificial intelligence (AI), there is no such thing as data overload. Because AI systems have the ability to process enormous amounts of data, and their accuracy increases along with data volume, the demand for data continues to grow. Consider, for example, an AI program designed to identify the cause of defective medical devices produced during the manufacturing process. As with any AI application, the software looks for patterns in the data using algorithms developed by data scientists. To try to solve this problem, suppose that the AI program receives and sorts through production data from different days of the week, times of day, machines and operators.

Structural causal models (SCMs), also known as (non-parametric) structural equation models (SEMs), are widely used for causal modeling purposes. A large body of theoretical results is available for the special case in which cycles are absent (i.e., acyclic SCMs, also known as recursive SEMs). However, in many application domains cycles are abundantly present, for example in the form of feedback loops. In this paper, we provide a general and rigorous theory of cyclic SCMs. The paper consists of two parts: the first part gives a rigorous treatment of structural causal models, dealing with measure-theoretic and other complications that arise in the presence of cycles. In contrast with the acyclic case, in cyclic SCMs solutions may no longer exist, or if they exist, they may no longer be unique, or even measurable in general. We give several sufficient and necessary conditions for the existence of (unique) measurable solutions. We show how causal reasoning proceeds in these models and how this differs from the acyclic case. Moreover, we give an overview of the Markov properties that hold for cyclic SCMs. In the second part, we address the question of how one can marginalize an SCM (possibly with cycles) to a subset of the endogenous variables. We show that under a certain condition, one can effectively remove a subset of the endogenous variables from the model, leading to a more parsimonious marginal SCM that preserves the causal and counterfactual semantics of the original SCM on the remaining variables. Moreover, we show how the marginalization relates to the latent projection and to latent confounders, i.e. latent common causes.